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hel lenic- journal-of-cardiology/EDITOR’S PAGEPulmonary arterial hypertension and quality of
life in cardiology. Do we really need more
studies?Cardiovascular medicine has significantly evolved over the
past three decades, as reflected by the decreasing inci-
dence of morbidity and mortality from myocardial in-
fractions and in the successful identification and
modification of a series of cardiovascular risk factors.1e5
Significant accomplishments have also been achieved in
understanding the diagnosis and treatment of pulmonary
hypertension, especially pulmonary arterial hypertension,
with the introduction of medicines in the clinical practice
capable of modifying symptoms and the physical history of
the disease.6,7 These achievements have oriented research
toward the improvement of the patient’s status and quality
of life. To this end, several studies have identified super-
vised exercise rehabilitation as capable of increasing
functional capacity and quality of life.8,9 However, these
studies are based on small sample sizes, and we are un-
aware of the specific rehabilitation practices that may
achieve the most significant and valuable improvements.
Interestingly, in this issue of Hellenic J Cardiol, Laoutaris ID
et al.10 present the results of supervised inspiratory muscle
training in the functional status and life quality of patients
with pulmonary hypertension. According to this pilot study,
high-intensity inspiratory muscle training may improve
dyspnea, exercise capacity and quality of life, emphasizing
the need for a holistic approach to managing this high-risk
group of patients.
However, pulmonary arterial hypertension, especially in
adults with congenital heart disease, remains relatively
rare and is difficult for inexperienced physicians to manage
(Table 1). These issues are elucidated by Giannakoulas G
and Gatzoulis MA in the recent issue of Hell J Cardiol (9).
These researchers propose the question of “whether the
patients must be treated according to established guide-
lines or with more aggressive protocols by specializedPeer review under responsibility of Hellenic Cardiological
Society.
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).physicians in tertiary centers”.11 Finally, the authors note
the need to further research this group of patients, espe-
cially patients with Eisenmenger syndrome, in tertiary
centers in collaboration with pulmonary arterial hyperten-
sion and adult congenital heart disease specialists.
Another interesting topic discussed in this issue of Hellenic
J of Cardiol is the Health Related Quality of Life in patients
with coronary artery disease after coronary revasculariza-
tion. Several studies have agreed on the superiority of
revascularization over medicine treatment alone, especially
in symptom relief, but also in survival.12,13 Moreover, a series
of scores have been introduced to select patients appropriate
for coronary artery stenting or coronary artery by-pass
grafting.14,15 Nevertheless, the issue of Health Related
Quality of Life after coronary artery stenting or coronary ar-
tery by-pass grafting has not been extensively addressed.
Takousi M et al. have analyzed data from 34 publications
involving 15,992 patients undergoing either type of revascu-
larization to conclusively address this topic. Interestingly
these researchers found that both types of revascularization
may improve patient Health Related Quality of Life, an issue
that may be of importance when patients are informed to
decide whether to comply with medical management or to
choose a revascularization procedure.16 Taken together,
these findings suggest that both the treatment of pulmonary
arterial hypertension and the improvement in quality of the
life after a cardiovascular event remain unresolved issues and
further studies are needed.
Two interesting studies from the region of Crete further
extend our knowledge concerning the quality of treatment in
the management of patients with arrhythmias. Implantable
cardioverter defibrillators (ICDs) have been established as
the gold standard treatment for themanagement of patients
with ventricular tachycardia.17 However, patients with ICDs
followed up for a long-term period present a significant
number of complications. Therefore, real world data
regarding the identification of patients most suitable for ICD
therapy is of importance. According to this long termElsevier B.V. This is an open access article under the CC BY-NC-ND
Table 1 Main drugs used in the treatment of Pulmonary
arterial hypertension.
Endothelin receptor antagonists
Bosentan Administration PO.
The first molecule of its class.
Dual endothelin receptor type A and B
antagonist
In patients at WHO-FC II, III or IV
Ambrisertan Administration PO.
Selective antagonists of endothelin receptor
type A.
In patients at WHO-FC II, III or IV
Macitentan Administration PO.
Newer Dual endothelin receptor type A and B
antagonist with fewer side effects
In patients at WHO-FC II, III or IV
Phosphodiesterase type 5 inhibitors
(enhance the NOecGMP pathway, slowing cGMP
degradation)
Sildenafil Administration PO. t.i.d
The first molecule of its class
In patients at WHO-FC II, III or IV
Tadalafil Administration PO. Once daily
In patients at WHO-FC II, III or IV
Vardenafil Administration PO. b.i.d
In patients at WHO-FC II, III or IV
Guanylate cyclase stimulators
(enhance cGMP production)
Riociguat Administration PO t.i.d
The only molecule of its category
It cannot be combined with
Phosphodiesterase type 5 inhibitors
In patients at WHO-FC II, III or IV
Prostacyclin analogues
Epoprostenol Administration IV. Short half-life (3e5 min) it
requires
cooling and continuous administration
In patients at WHO-FC III or IV
Iloprost Administration inhaled 6e8 times per day
In patients at WHO-FC III or IV
Treprostinil Administration mainly SC or IV
In patients at WHO-FC III or IV
Beraprost Administration PO
Novel agent
In patients at WHO-FC III
Prostacyclin receptor agonists
Selexipag Administration PO
Novel agent
In patients at WHO-FC III
216 Editor’s pageregistry18 (21 years) the frequency of complications is rela-
tively low (approximately 15%), while appropriate ICD ther-
apies were more frequent in patients selected for secondary
prevention. In addition, the time for the first appropriate
therapy was longer in patients selected for primary pre-
vention highlighting the need to extend the follow up period
to make conclusions about the absolute beneficial effect of
ICD therapy. Concerning atrial arrhythmias there is consis-
tent data from the past several years that new oralanticoagulants (NOAC) have a safer profile in patients with
non-valvular atrial fibrillation.19e21 However, as Papakon-
stantinou et al. observed,22 based on data from the emer-
gency department of a health center in southern Greece, the
implementation of NOACs is low, despite evidence from the
Danish registry showing a decline in the initiation of warfarin
among oral anticoagulation-naı¨ve atrial fibrillation pa-
tients.23 Possible reasons for these inconsistencies may be
the unwillingness of patients on previously established
vitamin K antagonist therapies to convert to newer treat-
ments, as well as the cost of NOACs.
Concerning coronary artery disease (CAD) management
and interventional procedures significant data are dis-
cussed in the review article of Hahalis G et al.24 Although
the radial artery approach has been established as prefer-
ential over the femoral arterial access site in many cen-
ters,25 especially due to the lower rates of complications
and patient preferences, the ulnar artery is most often
considered in cases in which the radial artery approach is
unsuccessful. However, as the authors emphasize once
arterial access is obtained the likelihood of a successful
coronary procedure is similar between the two forearm
arteries. Accordingly, based on a review of the literature
the authors conclude on the need for radial operators to
extend their skills and to adopt ulnar artery access as a
reasonable alternative in patients with unfavorable femoral
and radial artery characteristics. Despite the significant
improvements in interventional procedures, concerns
remain regarding the prevalence of high platelet reactivity
due to aspirin and clopidogrel resistance. Nevertheless,
based on previous reports and on data presented in this
issue from Dusan AD et al. there is no straight-forward as-
sociation between high platelet reactivity and cardiovas-
cular events.26e28 Moreover, cardiometabolic risk profile
has been identified as a factor associated with high platelet
reactivity that may shed light on previous reports between
the association of platelet reactivity and arterial wall
properties.29
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